[go: up one dir, main page]

ES2074037T1 - Dimero de la lisozima y composiciones que lo contienen. - Google Patents

Dimero de la lisozima y composiciones que lo contienen.

Info

Publication number
ES2074037T1
ES2074037T1 ES93915903T ES93915903T ES2074037T1 ES 2074037 T1 ES2074037 T1 ES 2074037T1 ES 93915903 T ES93915903 T ES 93915903T ES 93915903 T ES93915903 T ES 93915903T ES 2074037 T1 ES2074037 T1 ES 2074037T1
Authority
ES
Spain
Prior art keywords
necrosis factor
tumor necrosis
medicinal product
lysozyme
dimerized form
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES93915903T
Other languages
English (en)
Other versions
ES2074037T3 (es
Inventor
Witold Kiczka
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nika Health Products Ltd
Original Assignee
Nika Health Products Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nika Health Products Ltd filed Critical Nika Health Products Ltd
Publication of ES2074037T1 publication Critical patent/ES2074037T1/es
Application granted granted Critical
Publication of ES2074037T3 publication Critical patent/ES2074037T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/22Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
    • A61L15/32Proteins, polypeptides; Degradation products or derivatives thereof, e.g. albumin, collagen, fibrin, gelatin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/47Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/24Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2462Lysozyme (3.2.1.17)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Materials Engineering (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cardiology (AREA)
  • Microbiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • AIDS & HIV (AREA)
  • Rheumatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LA INVENCION SE REFIERE A LOS NUEVOS USOS DE LA FORMA DIMERIZADA DE LA LISOCIMA PARA LA FABRICACION DE UN MEDICAMENTO PARA INHIBIR LA BIOSINTESIS DEL FACTOR DE NECROSIS DE TUMOR EN ANIMALES Y HUMANOS. EL DIMERO DE LA LISOZIMA ES, EN PARTICULAR, UTIL PARA EL TRATAMIENTO Y LA PROFILAXIS DE TRASTORNOS ASOCIADOS CON NIVELES EXCESIVAMENTE ALTOS DE FACTOR DE NECROSIS DE TUMOR. LA INVENCION ADEMAS SE REFIERE A FORMULACIONES FARMACEUTICAS DEL MEDICAMENTO SEGUN LA INVENCION, ES DECIR INYECCIONES QUE CONSTAN DE LA FORMA DIMERIZADA DE LA LISOZIMA EN CANTIDADES DE 0,01-10 MG/ML, DE UNA COMPOSICION ESTERIL APIROGENICA QUE CONSTA DE AL MENOS UN SOLVENTE FISIOLOGICAMENTE ACEPTABLE Y AL MENOS UN PRESERVATIVO FARMACEUTICAMENTE APROBADO, TAMBIEN COMO TAMPONES Y VENDAJES ANTISEPTICOS IMPREGNADOS CON EL, Y POMADAS O GELES QUE CONSTAN DE UNA DOSIS EFECTIVA DE LA FORMA DIMERIZADA DE LA LISOZIMA PARA LA PREVENCION Y/O TRATAMIENTO DE SEPSIS Y DE CONMOCION SEPTICA, ESPECIALMENTE DE HERIDAS INFECTADAS.
ES93915903T 1992-07-13 1993-07-13 Uso del dimero de lisozima para la fabricacion de un medicamento para modular los mecanismos de defensa naturales. Expired - Lifetime ES2074037T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PL92295273A PL173978B1 (pl) 1992-07-13 1992-07-13 Sposób oddziaływania na wydzielanie cytokin w hodowli limfocytów krwi obwodowej
PL29527392 1992-07-13

Publications (2)

Publication Number Publication Date
ES2074037T1 true ES2074037T1 (es) 1995-09-01
ES2074037T3 ES2074037T3 (es) 2004-07-01

Family

ID=20058087

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93915903T Expired - Lifetime ES2074037T3 (es) 1992-07-13 1993-07-13 Uso del dimero de lisozima para la fabricacion de un medicamento para modular los mecanismos de defensa naturales.

Country Status (31)

Country Link
US (1) US6132715A (es)
EP (1) EP0651654B1 (es)
JP (1) JPH07508744A (es)
KR (1) KR100289841B1 (es)
CN (1) CN1057937C (es)
AT (1) ATE252392T1 (es)
AU (1) AU677786B2 (es)
BG (1) BG63331B1 (es)
BR (1) BR9306722A (es)
CA (1) CA2140140A1 (es)
CZ (1) CZ286725B6 (es)
DE (2) DE651654T1 (es)
DK (1) DK0651654T3 (es)
ES (1) ES2074037T3 (es)
FI (1) FI950144A7 (es)
GE (1) GEP20012466B (es)
GR (1) GR950300039T1 (es)
HU (1) HU218151B (es)
MX (1) MX9304197A (es)
NZ (2) NZ254135A (es)
OA (1) OA10125A (es)
PL (1) PL173978B1 (es)
PT (1) PT651654E (es)
RO (1) RO112580B1 (es)
RU (1) RU2145875C1 (es)
SG (1) SG52727A1 (es)
SK (1) SK282377B6 (es)
TW (1) TW259710B (es)
UA (1) UA49789C2 (es)
WO (1) WO1994001127A1 (es)
ZA (1) ZA935046B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6183742B1 (en) 1992-07-13 2001-02-06 Nika Health Products, Limited Applications of lysozyme dimer
DZ1964A1 (fr) * 1995-01-13 2002-10-15 Nika Health Products Ltd Nouvelle applications d'un dimère de lysozyme.
WO1996038115A1 (en) * 1995-05-30 1996-12-05 Lectin Biopharma, Inc. Method of using lectins for agglutination and collection of menstrual flow
US6123937A (en) * 1997-03-14 2000-09-26 Nika Health Products, Limited Applications of lysozyme dimer
ITMI981148A1 (it) * 1998-05-22 1999-11-22 Therapicon Srl Utilizzo di lisozima c modificato per preparare composizioni medicinali per il trattamento di alcune gravi malattie
EP1174147A1 (en) * 2000-06-27 2002-01-23 Nika Health Products Limited Reversal of antibiotic resistance with lysozyme dimer
US20050244402A1 (en) * 2004-04-30 2005-11-03 Villanueva Julie M Absorption of pain-causing agents
RU2320367C1 (ru) * 2006-08-22 2008-03-27 Государственное образовательное учреждение дополнительного профессионального образования Российская медицинская академия последипломного образования Федерального агентства по здравоохранению и социальному развитию (ГОУ ДПО РМАПО Росздрава) Способ сопроводительного лечения острого лимфобластного лейкоза
RU2351351C1 (ru) * 2007-08-08 2009-04-10 Тихоокеанский Институт Биоорганической Химии Дальневосточного Отделения Российской Академии Наук (Тибох Дво Ран) Средство, повышающее неспецифическую сопротивляемость организма к бактериальным эндотоксинам
RU2472467C2 (ru) * 2011-04-13 2013-01-20 Государственное научное учреждение Краснодарский научно-исследовательский ветеринарный институт (ГНУ КНИВИ) Способ профилактики и лечения гастроэнтеритов, обусловленных бактериозами, у телят
CN105106626A (zh) * 2015-09-30 2015-12-02 成都倍加特生物科技有限公司 一种治疗月经期感染的汤剂药物及其制备方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR4020M (es) * 1965-01-29 1966-03-21
FR2215201A1 (en) * 1973-01-24 1974-08-23 Theranol Lab Broad-spectrum antibiotic compsns. - contg. antibiotic resistant lactic bacilli and enzyme diffusing-agent
JPS5533409A (en) * 1978-08-30 1980-03-08 Eisai Co Ltd Carcinostatic agent
JPS5533408A (en) * 1978-08-30 1980-03-08 Eisai Co Ltd Immunity-increasing agent
JPS5543040A (en) * 1978-09-25 1980-03-26 Eisai Co Ltd Immunity raising agent
US4221794A (en) * 1979-06-21 1980-09-09 Newport Pharmaceuticals International, Inc. Method of imparting immunomodulating and antiviral activity
US4457919A (en) * 1980-03-14 1984-07-03 Newport Pharmaceutical International, Inc. Method of imparting immunomodulating, antiviral or antitumor activity
US4510144A (en) * 1981-08-26 1985-04-09 Newport Pharmaceuticals International Methods of imparting immunomodulating activity with dihydrothiazolo purine derivatives
US4739046A (en) * 1985-08-19 1988-04-19 Luzio Nicholas R Di Soluble phosphorylated glucan
US4744984A (en) * 1985-10-08 1988-05-17 Vetrepharm Research, Inc. Antiviral immunotherapeutic agent and preparation thereof
EP0238851B1 (en) * 1986-02-19 1992-12-09 Imreg, Inc. A method and means of assaying an immune system
HU204710B (en) * 1988-05-26 1992-02-28 Nika Health Products Inc Process for producing pharmaceutical compositions having antiviral and antibacterial effect
DE3817955A1 (de) * 1988-05-27 1989-11-30 Hoechst Ag Tnf-inhibitor enthaltendes arzneimittel
AU3765689A (en) * 1988-05-31 1990-01-05 Napp Systems (U.S.A.) Inc. Apparatus and process for processing printing plates
CA2060309A1 (en) * 1989-06-13 1990-12-14 Alison M. Badger Inhibition of interleukin-1 and tumor necrosis factor production by monocytes and/or macrophages
US5314816A (en) * 1990-01-08 1994-05-24 Nika Health Products Ltd. Method of preparing lysozyme dimers
CA2073351C (en) * 1990-01-08 2001-10-16 Peter Herrmann Lysozyme dimers and method of preparing them
ATE161720T1 (de) * 1990-08-03 1998-01-15 Smithkline Beecham Corp Tnf-inhibitoren

Also Published As

Publication number Publication date
CZ286725B6 (en) 2000-06-14
JPH07508744A (ja) 1995-09-28
ES2074037T3 (es) 2004-07-01
AU677786B2 (en) 1997-05-08
AU4568693A (en) 1994-01-31
CA2140140A1 (en) 1994-01-20
PL173978B1 (pl) 1998-05-29
MX9304197A (es) 1994-02-28
ATE252392T1 (de) 2003-11-15
RO112580B1 (ro) 1997-11-28
EP0651654B1 (en) 2003-10-22
OA10125A (en) 1996-12-18
SK4095A3 (en) 1995-09-13
NZ254135A (en) 1996-11-26
PL295273A1 (en) 1994-01-24
TW259710B (es) 1995-10-11
CN1087278A (zh) 1994-06-01
SK282377B6 (sk) 2002-01-07
GR950300039T1 (en) 1995-07-31
KR100289841B1 (ko) 2001-05-15
HU9500098D0 (en) 1995-03-28
CN1057937C (zh) 2000-11-01
ZA935046B (en) 1994-02-07
KR950702432A (ko) 1995-07-29
HU218151B (hu) 2000-06-28
FI950144L (fi) 1995-01-12
FI950144A0 (fi) 1995-01-12
GEP20012466B (en) 2001-06-25
NZ299377A (en) 2001-02-23
DK0651654T3 (da) 2004-02-23
BR9306722A (pt) 1998-12-08
DE651654T1 (de) 1996-01-04
RU2145875C1 (ru) 2000-02-27
SG52727A1 (en) 1998-09-28
HUT70973A (en) 1995-11-28
EP0651654A1 (en) 1995-05-10
BG99287A (bg) 1995-08-28
PT651654E (pt) 2004-03-31
US6132715A (en) 2000-10-17
CZ8595A3 (en) 1995-09-13
FI950144A7 (fi) 1995-01-12
DE69333258T2 (de) 2004-08-26
DE69333258D1 (de) 2003-11-27
WO1994001127A1 (en) 1994-01-20
UA49789C2 (uk) 2002-10-15
BG63331B1 (bg) 2001-10-31

Similar Documents

Publication Publication Date Title
AR054064A1 (es) Composicio con ingrediente farmaceutico activo en base a canabinoide para formas de dosis mejoradas
ES2176190T3 (es) Inhibidores de la actividad de esteroides sexuales.
ES2118834T3 (es) Sistema mejorado de penetracion en la piel para la administracion topica mejorada de farmacos.
SE8503664L (sv) Ett system for tillforsel av lekemedel
ES2156840T1 (es) Medicamento que contiene polisulfato de pentosano e implante para tratar la fibrosis.
ES2074037T1 (es) Dimero de la lisozima y composiciones que lo contienen.
MY117892A (en) Therapeutic compounds
GEP20033131B (en) Azabicycloalkanes as CCR5 Modulators, Pharmaceutical Compositions Containing the Same and Their Use for Treatment and Prevention of Diseases Caused by CCR5 Activity
ES2137456T3 (es) Agente de tratamiento de las enfermedades hepato-biliares.
ES2171469T3 (es) Composicion administrada por via nasal y preparacion que la contiene.
ES2126114T3 (es) Composiciones liquidas estables de interferon gamma.
BR9814299A (pt) Aminobiguanidas e o seu uso para desinfetarlentes de contato e preservar composiçõesfarmacêuticas
SE8001599L (sv) Transdermalt medicineringssystem for isosorbiddinitrat
MX9400800A (es) Un complejo de estabilizacion neutro para ci-979 hci, un activador de la cognicion.
ES2054690T3 (es) Uso farmaceutico de extractos de gramineas.
IT1170214B (it) Composizione farmaceutica per la cura delle arteriopatie periferiche
ATE257704T1 (de) Pharmazeutische zusammensetzungen enthaltend norastemizol.
BR0309057A (pt) Formulações lìquidas com baixa dosagem em entecavir e uso
ES2087623T3 (es) Derivados de bencimidazol como agente antimicrobiano contra campylobacter pylon.
ES2091183T3 (es) Metodo para mejorar el sueño.
AR045263A1 (es) Metodo, kit y composicion farmaceutica para tratar infecciones virales
RU95105517A (ru) Применение димера лизоцима в качестве лекарственного средства и содержащие его композиции
MX9203361A (es) Composiciones farmaceuticas que contienen cloruro de galio.
AR026631A1 (es) ''3-4-dihidroquinazolinas 5,6-disustituidas''
ES2182504T3 (es) Bifenilsulfonilcianamidas, procedimiento para su preparacion y su utilizacion como medicamento.